Yahoo
NasdaqCM - Delayed Quote USD

Yarrow Bioscience Inc (YARW)

15.60 +2.00 (+14.71%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for YARW
  • Previous Close 13.60
  • Open 13.80
  • Bid 14.78 x 100
  • Ask 15.58 x 100
  • Day's Range 13.62 - 15.94
  • 52 Week Range 12.39 - 46.95
  • Volume 229,754
  • Avg. Volume 133,181
  • Market Cap (intraday) 145.148M
  • Beta (5Y Monthly) 2.13
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 58.00
  • Moby Rating Neutral

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

www.yarrowbioscience.com

7

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

YARW
4.70%
S&P 500 (^GSPC)
7.76%

1-Year Return

YARW
56.58%
S&P 500 (^GSPC)
9.77%

3-Year Return

YARW
83.04%
S&P 500 (^GSPC)
68.96%

5-Year Return

YARW
97.76%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -6.51M
Profit Margin 0.00%

Q2

FY26

-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

56.00
58.00 Average
15.60 Current
60.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/6/2026
Analyst Guggenheim
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 60

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -283.98M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18.67M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: